In case you missed it, on Nov. 20, the Centers for Medicare & Medicaid Services (CMS), a department within the U.S. Department of Health and Human Services, announced that it will overhaul the payment system for Medicare Part B (i.e., infusion) drugs on Jan. 1, 2021. The plan is called the Most Favored Nation (MFN)…
In this ACR Convergence session, Jason R. Kolfenbach, MD, & John H. Stone, MD, MPH, shared clinical insights about rheumatic diseases.
During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.
Researchers found half of patients taking the biosimilar infliximab-dyyb (Inflectra) remained highly adherent to medication use after 12 months.
In rural America, where rheumatology offices are fewer and farther between, the expansion of telemedicine has been a boon during the COVID-19 pandemic. However, lab closures and reduced hospital services have made monitoring patients’ medications more challenging.
The Global Rheumatology Alliance is an important tool for assessing COVID-19 risk, & the ACR COVID-19 Task Force provides treatment guidance to rheumatology practitioners.
The use of warfarin may increase the risk of knee or hip replacement in patients with osteoarthritis (OA), according to research presented during ACR Convergence 2020.
The FDA issued an emergency use authorization for the use of baricitinib combined with remdesivir to treat patients hospitalized with COVID-19.
With his clinic resuming in-person visits, Jay Mehta, MD, says his patients and staff have proved remarkably adaptable, embracing telemedicine during the early days of the pandemic and now facemasks during appointments.
According to a recent phase 3 study, tofacitinib may be a safe and effective treatment for adult patients with ankylosing spondylitis (AS).